BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/12/2024 3:43:33 AM | Browse: 123 | Download: 497
 |
Received |
|
2024-07-22 14:57 |
|
Peer-Review Started |
|
2024-07-22 14:57 |
|
First Decision by Editorial Office Director |
|
2024-08-21 22:49 |
|
Return for Revision |
|
2024-08-21 22:49 |
|
Revised |
|
2024-09-03 15:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-09-25 02:36 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-25 06:22 |
|
Articles in Press |
|
2024-09-25 06:22 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-30 04:49 |
|
Publish the Manuscript Online |
|
2024-10-12 03:43 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Elafibranor: A promising treatment for alcohol-associated liver disease?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hong Wei, Li-Xuan Sang and Bing Chang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Bing Chang, MD, PhD, Chief Physician, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com |
| Key Words |
Alcohol-associated liver disease; Liver fibrosis; Gut barrier function; Peroxisome proliferator activated receptor; Ethanol |
| Core Tip |
This article discusses the article by Koizumi et al on the effects of elafibranor (EFN) in treating alcohol-associated liver disease (ALD) in a mouse model. These findings are remarkable and reveal that EFN can significantly increase intestinal barrier function and ameliorate liver fibrosis. Given that the efficacy and safety of EFN have been established in patients with primary biliary cholangitis, it has emerged as an exceedingly promising candidate novel treatment modality for ALD. |
| Publish Date |
2024-10-12 03:43 |
| Citation |
Wei H, Sang LX, Chang B. Elafibranor: A promising treatment for alcohol-associated liver disease? World J Gastroenterol 2024; 30(39): 4313-4317 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i39/4313.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i39.4313 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
